MA56466A - Anticorps anti-epha4 - Google Patents

Anticorps anti-epha4

Info

Publication number: MA56466A
Authority: MA; Morocco
Prior art keywords: epha4 antibodies; epha4; antibodies
Prior art date: 2019-07-01

Application number

MA056466A

Other languages

English (en)

Inventor

Maki Deguchi

Toshio Imai

Eiji Inoue

Tomomi Kawakatsu

Aki Nakatani

Akio Yamada

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-07-01

Filing date

2020-06-29

Publication date

2022-05-11

2020-06-29 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2022-05-11 Publication of MA56466A publication Critical patent/MA56466A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA056466A 2019-07-01 2020-06-29 Anticorps anti-epha4 MA56466A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2019122982		2019-07-01

Publications (1)

Publication Number	Publication Date
MA56466A true MA56466A (fr)	2022-05-11

Family

ID=74066003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA056466A MA56466A (fr)	2019-07-01	2020-06-29	Anticorps anti-epha4

Country Status (23)

Country	Link
US (2)	US10947313B2 (fr)
EP (1)	EP3995582A4 (fr)
JP (2)	JP6979147B2 (fr)
KR (1)	KR20220027825A (fr)
CN (2)	CN117398459A (fr)
AR (1)	AR119303A1 (fr)
AU (1)	AU2020300205A1 (fr)
BR (1)	BR112021025161A2 (fr)
CA (1)	CA3139398A1 (fr)
CL (1)	CL2021003326A1 (fr)
CO (1)	CO2021016588A2 (fr)
IL (1)	IL287828A (fr)
JO (1)	JOP20210333A1 (fr)
MA (1)	MA56466A (fr)
MX (1)	MX2021015298A (fr)
MY (1)	MY207780A (fr)
PE (1)	PE20220570A1 (fr)
PH (1)	PH12021553090A1 (fr)
SG (1)	SG11202112433VA (fr)
TW (3)	TWI808882B (fr)
UA (1)	UA129772C2 (fr)
WO (1)	WO2021002312A1 (fr)
ZA (1)	ZA202108836B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019023247A1 (fr)	2017-07-25	2019-01-31	Immutics, Inc.	Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand
JP2022523333A (ja)	2019-01-30	2022-04-22	トゥルーバインディング，インコーポレイテッド	抗ｇａｌ３抗体およびその使用
MY207780A (en)	2019-07-01	2025-03-18	Eisai R&D Man Co Ltd	Anti-epha4 antibody
EP4157338A4 (fr)	2020-05-26	2024-11-13	TrueBinding, Inc.	Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
CN116710133A (zh) *	2020-12-24	2023-09-05	卫材R&D管理有限公司	肌萎缩侧索硬化的治疗用药物组合物
KR20240099197A (ko) *	2021-11-11	2024-06-28	에자이 알앤드디 매니지먼트 가부시키가이샤	항-EphA4 항체
WO2025151607A1 (fr) *	2024-01-10	2025-07-17	Santa Ana Bio, Inc.	Méthodes et compositions pour le traitement de maladies auto-immunes, allergiques et inflammatoires

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1094731A (en)	1911-06-06	1914-04-28	Lucien Linden	Oxidizing process.
JP2824433B2 (ja)	1988-12-09	1998-11-11	財団法人化学及血清療法研究所	新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
AU629554B2 (en)	1988-06-24	1992-10-08	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Exogenous gene expression vector containing chick beta-actin gene promoter
JP3680114B2 (ja)	1993-09-17	2005-08-10	敏一中村	脳神経障害治療剤
US5902732A (en)	1995-10-04	1999-05-11	Cytoscan Sciences Llc	Drug screening process measuring changes in cell volume
US20020068361A1 (en)	1997-04-08	2002-06-06	Douglas Clary	Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU6887698A (en)	1997-04-08	1998-10-30	Sugen, Inc.	Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US5876946A (en)	1997-06-03	1999-03-02	Pharmacopeia, Inc.	High-throughput assay
US20070015145A1 (en)	2001-08-14	2007-01-18	Clifford Woolf	Nucleic acid and amino acid sequences involved in pain
US20060241074A1 (en)	2001-08-14	2006-10-26	The General Hospital Corporation	Methods for treatment of pain
US20070026409A1 (en)	2001-08-14	2007-02-01	The General Hospital Corporation	Nucleic acid and amino acid sequences involved in pain
JP2003169699A (ja)	2001-12-10	2003-06-17	Japan Science & Technology Corp	特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja)	2002-05-31	2004-01-08	Otsuka Pharmaceut Co Ltd	アミロイドβ産生に影響を与える化合物のスクリーニング方法
WO2004028551A1 (fr)	2002-09-24	2004-04-08	The Burnham Institute	Nouveaux agents modulant l'activite du recepteur eph
HRP20050461A2 (en)	2002-11-26	2005-08-31	Pharmacia & Upjohn Company Llc	Soluble notch-based substrates for gamma secretase and methods and compositions for using same
US7604799B2 (en)	2003-06-06	2009-10-20	Medimmune, Llc	EphA4 Antibodies
WO2005045028A1 (fr)	2003-11-10	2005-05-19	Osaka Industrial Promotion Organization	Procede d'analyse acellulaire du clivage de notch et procede d'identification de medicaments par criblage
WO2005083086A2 (fr)	2004-02-27	2005-09-09	Oncotherapy Science, Inc.	L'EphA4 COMME CIBLE THÉRAPEUTIQUE DU PCR ET DU PDACa
NZ553273A (en)	2004-09-08	2009-11-27	Univ Melbourne	Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling
EP1662259A1 (fr)	2004-11-25	2006-05-31	Cellzome Ag	Utilisation des inhibiteurs du récepteur Eph pour le traitement des maladies neurodégénératives
GB0427023D0 (en)	2004-12-09	2005-01-12	Merck Sharp & Dohme	Assay method
KR20080105111A (ko)	2006-02-28	2008-12-03	온코세라피 사이언스 가부시키가이샤	항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
EP1947193A1 (fr)	2007-01-17	2008-07-23	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Procédé de criblage pour composés antidiabétiques
ATE546543T1 (de)	2007-06-08	2012-03-15	Eisai R&D Man Co Ltd	Screening-verfahren mit verwendung des neuen substrats epha4 für gamma-sekretase
JP2010533478A (ja)	2007-07-13	2010-10-28	エランファーマシューティカルズ，インコーポレイテッド	ガンマセクレターゼの阻害剤の基質特異性を同定するための組成物および方法
JPWO2009011426A1 (ja)	2007-07-19	2010-09-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	γ−セクレターゼの新規基質ｃ−Ｍｅｔを利用したスクリーニング方法
WO2009017234A1 (fr)	2007-08-01	2009-02-05	Eisai R & D Management Co., Ltd.	Procédé de criblage utilisant le nouveau substrat c-ret pour la gamma-sécrétase
EP2031064A1 (fr)	2007-08-29	2009-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Procédé d'augmentation de titres de protéines
US20090163594A1 (en)	2007-10-31	2009-06-25	Elan Pharmaceuticals, Inc.	Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US8530181B2 (en)	2007-11-15	2013-09-10	Eisai R&D Management Co., Ltd.	Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
JP5508857B2 (ja) *	2007-11-30	2014-06-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	新規活性を有するＥｐｈＡ４ポリペプチドおよびその用途
US20100113415A1 (en)	2008-05-29	2010-05-06	Rajapakse Hemaka A	Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2260864A1 (fr)	2009-06-10	2010-12-15	University of Melbourne	Applications thérapeutiques
JP2010285413A (ja)	2009-06-10	2010-12-24	Univ Of Melbourne	治療用途
DK2653552T3 (en)	2010-12-17	2017-01-16	Eisai R&D Man Co Ltd	SCREENING METHOD USING GELATINASE-MEDIATED EphA4 DIVISION REACTION AS INDICATOR
US9784751B2 (en)	2011-04-25	2017-10-10	Eisai R&D Management Co., Ltd.	Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
GB201107996D0 (en)	2011-05-13	2011-06-29	Vib Vzw	EphA4 is a diease modifier in motor neuron disease
EP3473271B1 (fr)	2014-07-31	2022-07-20	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Anticorps monoclonaux humains dirigés contre epha4 et leur utilisation
AR105938A1 (es) *	2015-09-08	2017-11-22	Eisai R&D Man Co Ltd	Anticuerpo anti-epha4
MY207780A (en)	2019-07-01	2025-03-18	Eisai R&D Man Co Ltd	Anti-epha4 antibody

2020
- 2020-06-29 MY MYPI2021006929A patent/MY207780A/en unknown
- 2020-06-29 PE PE2021002077A patent/PE20220570A1/es unknown
- 2020-06-29 CN CN202311449611.XA patent/CN117398459A/zh active Pending
- 2020-06-29 BR BR112021025161A patent/BR112021025161A2/pt unknown
- 2020-06-29 CA CA3139398A patent/CA3139398A1/fr active Pending
- 2020-06-29 MX MX2021015298A patent/MX2021015298A/es unknown
- 2020-06-29 KR KR1020217038552A patent/KR20220027825A/ko active Pending
- 2020-06-29 TW TW111133484A patent/TWI808882B/zh active
- 2020-06-29 CN CN202080039114.0A patent/CN113906050B/zh active Active
- 2020-06-29 TW TW109121908A patent/TWI779307B/zh active
- 2020-06-29 MA MA056466A patent/MA56466A/fr unknown
- 2020-06-29 EP EP20834769.0A patent/EP3995582A4/fr active Pending
- 2020-06-29 SG SG11202112433VA patent/SG11202112433VA/en unknown
- 2020-06-29 JO JOP/2021/0333A patent/JOP20210333A1/ar unknown
- 2020-06-29 US US16/915,412 patent/US10947313B2/en active Active
- 2020-06-29 PH PH1/2021/553090A patent/PH12021553090A1/en unknown
- 2020-06-29 AR ARP200101834A patent/AR119303A1/es unknown
- 2020-06-29 UA UAA202106526A patent/UA129772C2/uk unknown
- 2020-06-29 AU AU2020300205A patent/AU2020300205A1/en active Pending
- 2020-06-29 WO PCT/JP2020/025465 patent/WO2021002312A1/fr not_active Ceased
- 2020-06-29 JP JP2021519890A patent/JP6979147B2/ja active Active
- 2020-06-29 TW TW112123862A patent/TWI866304B/zh active
2021
- 2021-01-08 US US17/145,001 patent/US11136400B2/en active Active
- 2021-11-03 IL IL287828A patent/IL287828A/en unknown
- 2021-11-09 ZA ZA2021/08836A patent/ZA202108836B/en unknown
- 2021-11-12 JP JP2021184594A patent/JP7072114B2/ja active Active
- 2021-12-07 CO CONC2021/0016588A patent/CO2021016588A2/es unknown
- 2021-12-13 CL CL2021003326A patent/CL2021003326A1/es unknown

Also Published As

Publication number	Publication date
UA129772C2 (uk)	2025-07-30
MX2021015298A (es)	2022-01-18
AR119303A1 (es)	2021-12-09
US20210171644A1 (en)	2021-06-10
BR112021025161A2 (pt)	2022-01-25
JP7072114B2 (ja)	2022-05-19
CN113906050A (zh)	2022-01-07
AU2020300205A1 (en)	2022-01-20
IL287828A (en)	2022-01-01
KR20220027825A (ko)	2022-03-08
MY207780A (en)	2025-03-18
TW202115116A (zh)	2021-04-16
EP3995582A1 (fr)	2022-05-11
US11136400B2 (en)	2021-10-05
TW202248216A (zh)	2022-12-16
CA3139398A1 (fr)	2021-01-07
JP6979147B2 (ja)	2021-12-08
SG11202112433VA (en)	2021-12-30
CL2021003326A1 (es)	2022-07-22
PE20220570A1 (es)	2022-04-20
NZ783106A (en)	2025-08-29
CN117398459A (zh)	2024-01-16
TWI779307B (zh)	2022-10-01
JP2022031271A (ja)	2022-02-18
ZA202108836B (en)	2023-04-26
PH12021553090A1 (en)	2022-07-25
EP3995582A4 (fr)	2023-01-18
WO2021002312A1 (fr)	2021-01-07
CO2021016588A2 (es)	2022-04-08
CN113906050B (zh)	2023-11-21
TWI866304B (zh)	2024-12-11
TWI808882B (zh)	2023-07-11
JPWO2021002312A1 (ja)	2021-09-13
US20210002378A1 (en)	2021-01-07
US10947313B2 (en)	2021-03-16
TW202342101A (zh)	2023-11-01
JOP20210333A1 (ar)	2023-01-30

Publication	Publication Date	Title
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
MA52742A (fr)	2021-04-14	Anticorps bispécifiques dll3-cd3
EP3836960A4 (fr)	2022-05-11	Anticorps cd47 thérapeutiques
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA52212A (fr)	2021-02-17	Anticorps multivalent
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA55600A (fr)	2022-02-16	Anticorps anti-ige
EP3752536A4 (fr)	2022-05-11	Anticorps anti-her2
EP3995582A4 (fr)	2023-01-18	Anticorps anti-epha4
EP4081547A4 (fr)	2024-02-21	Nouveaux anticorps anti-fgfr2b
MA52152A (fr)	2021-01-20	Anticorps
EP3831851A4 (fr)	2022-04-27	Anticorps anti-btla
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP4271712A4 (fr)	2025-05-07	Anticorps anti-hvem
EP3746120A4 (fr)	2021-11-24	Anticorps anti-pd-1
MA51135A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
MA55705A (fr)	2022-02-23	Anticorps bispécifiques
EP3852779A4 (fr)	2022-06-08	Anticorps anti-klrg1
MA50654A (fr)	2020-08-05	Anticorps anti-pacap